AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34583214 — intervention group
Group type: COMPARATOR
Intervention: IFN-placebo
Number of subjects: 80
Study 33874971 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-domain responder index (MDRI)
Number of subjects: 0
Study 33874971 — intervention group
Group type: COMPARATOR
Intervention: Traditional clinical trial design
Number of subjects: 0
Study 32011684 — intervention group
Group type: EXPERIMENTAL
Intervention: Right-truncated Poisson-distributed outcomes
Number of subjects: 0
Study 35674613 — intervention group
Group type: EXPERIMENTAL
Intervention: T. harzianum with 50 g of NPK treatment (T2)
Number of subjects: 5
Study 35674613 — intervention group
Group type: EXPERIMENTAL
Intervention: B. thuringiensis plus 50 g NPK treatment (T3)
Number of subjects: 5
Study 35674613 — intervention group
Group type: EXPERIMENTAL
Intervention: B. thuringiensis with 25 g NPK fertilizer treatment (T5)
Number of subjects: 5
Study 35674613 — intervention group
Group type: EXPERIMENTAL
Intervention: Soil inoculation of B. thuringiensis
Number of subjects: 5
Study 32808394 — intervention group
Group type: EXPERIMENTAL
Intervention: Horse riding simulator (HRS) along with conventional physiotherapy
Number of subjects: 30
Study 32808394 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 30
Study 35333363 — intervention group
Group type: EXPERIMENTAL
Intervention: Team-based empowered care group
Number of subjects: 2393
Study 35333363 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowered care group
Number of subjects: 2393
Study 35333363 — intervention group
Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 2393
Study 35333363 — intervention group
Group type: COMPARATOR
Intervention: Team-based empowered care group vs usual care group
Number of subjects: 2393
Study 35333363 — intervention group
Group type: COMPARATOR
Intervention: Team-based empowered care group vs empowered care group
Number of subjects: 2393
Study 35333363 — intervention group
Group type: EXPERIMENTAL
Intervention: Attainment of multiple treatment targets
Number of subjects: 2393
Study 32272501 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (KEYTRUDA)
Number of subjects: 50
Study 33908296 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 µg roflumilast
Number of subjects: 10
Study 33908296 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 µg roflumilast
Number of subjects: 10
Study 33908296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 32036644 — intervention group
Group type: EXPERIMENTAL
Intervention: ALPPS procedure
Number of subjects: 1000
Study 35667389 — intervention group
Group type: EXPERIMENTAL
Intervention: RFA followed by SEMS insertion (RFA+SEMS, n = 42)
Number of subjects: 86
Study 35667389 — intervention group
Group type: COMPARATOR
Intervention: SEMS only (n = 44)
Number of subjects: 86
Study 35667389 — intervention group
Group type: EXPERIMENTAL
Intervention: RFA followed by SEMS insertion (RFA+SEMS)
Number of subjects: 86
Study 35667389 — intervention group
Group type: COMPARATOR
Intervention: SEMS only
Number of subjects: 86
Study 32773431 — intervention group
Group type: EXPERIMENTAL
Intervention: Total resection of the cystic lesion
Number of subjects: 30
Study 35766037 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of candesartan and carvedilol plus standard of care
Number of subjects: 0
Study 35766037 — intervention group
Group type: COMPARATOR
Intervention: Standard of care alone
Number of subjects: 0
Study 33651099 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab plus CHOP (8 cycles of 21 days)
Number of subjects: 1418
Study 33651099 — intervention group
Group type: COMPARATOR
Intervention: Rituximab plus CHOP (6 or 8 cycles)
Number of subjects: 1418
Study 35988057 — intervention group
Group type: EXPERIMENTAL
Intervention: EPI-589 (500 mg twice daily)
Number of subjects: 68
Study 35988057 — intervention group
Group type: EXPERIMENTAL
Intervention: EPI-589 (750 mg twice daily)
Number of subjects: 68
Study 35988057 — intervention group
Group type: EXPERIMENTAL
Intervention: EPI-589 (1000 mg single daily dose)
Number of subjects: 68
Study 35988057 — intervention group
Group type: EXPERIMENTAL
Intervention: EPI-589 (250-1000 mg single doses)
Number of subjects: 68
Study 35988057 — intervention group
Group type: EXPERIMENTAL
Intervention: EPI-589 under fasting conditions
Number of subjects: 68
Study 35988057 — intervention group
Group type: EXPERIMENTAL
Intervention: EPI-589 under fed conditions
Number of subjects: 68
Study 35988057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 34742669 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Intervention in OBEsity (IGOBE) program with weekly sessions for six weeks
Number of subjects: 437
Study 34742669 — intervention group
Group type: COMPARATOR
Intervention: Usual care therapy (Control Group)
Number of subjects: 437
Study 34742669 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Intervention in OBEsity (IGOBE) program
Number of subjects: 437
Study 33157551 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery for colorectal cancer
Number of subjects: 2824
Study 35742618 — intervention group
Group type: EXPERIMENTAL
Intervention: Judo4Balance program (n = 100)
Number of subjects: 200
Study 35742618 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 100)
Number of subjects: 200
Study 32969828 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerometry data collection using Actigraph GT9X accelerometer
Number of subjects: 580
Study 32969828 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity tracking
Number of subjects: 580
Study 32969828 — intervention group
Group type: EXPERIMENTAL
Intervention: No other characteristics
Number of subjects: 580
Study 32969828 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall protocol for accelerometry data collection
Number of subjects: 580
Study 35183768 — intervention group
Group type: EXPERIMENTAL
Intervention: AFI-guided probe-based confocal laser endomicroscopy (pCLE)
Number of subjects: 154
Study 35183768 — intervention group
Group type: COMPARATOR
Intervention: High-resolution white-light endoscopy (HRWLE) with Seattle protocol biopsies
Number of subjects: 154
Study 35183768 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-biomarker panel (pCLE optical dysplasia, aberrant p53, and aneuploidy)
Number of subjects: 154
Study 32736592 — intervention group
Group type: EXPERIMENTAL
Intervention: EDP1815 (2 capsules twice daily for up to 7 days, with an option to extend to 14 days)
Number of subjects: 125
Study 32736592 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin (10mg once daily) and Ambrisentan (5mg once daily for up to 14 days)
Number of subjects: 125
Study 32736592 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 125
Study 33725995 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics given orally for 8 weeks
Number of subjects: 192
Study 33725995 — intervention group
Group type: COMPARATOR
Intervention: Placebo given orally for 8 weeks
Number of subjects: 192
Study 33723675 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional support
Number of subjects: 327
Study 33723675 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumental support
Number of subjects: 327
Study 33723675 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue
Number of subjects: 327
Study 33723675 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain interference
Number of subjects: 327
Study 32051002 — intervention group
Group type: EXPERIMENTAL
Intervention: Intimacy Enhancement (IE) intervention
Number of subjects: 120
Study 32051002 — intervention group
Group type: COMPARATOR
Intervention: Living Healthy Together (control condition)
Number of subjects: 120
Study 33998179 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy
Number of subjects: 105
Study 33998179 — intervention group
Group type: EXPERIMENTAL
Intervention: Ahmed glaucoma valve (AGV)
Number of subjects: 105
Study 33998179 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans‐scleral diode laser cyclophotocoagulation (TDLC)
Number of subjects: 105
Study 32883108 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 4744
Study 32883108 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4744
Study 35158135 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious game simulation (SGS) based training
Number of subjects: 90
Study 35158135 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional training)
Number of subjects: 90
Study 32785614 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 27342
Study 32785614 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27342
Study 35385557 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (ITM) 0.2 mg before general anesthesia
Number of subjects: 38
Study 35385557 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (ITM)
Number of subjects: 38
Study 35385557 — intervention group
Group type: COMPARATOR
Intervention: Control group (general anesthesia only)
Number of subjects: 38
Study 33253662 — intervention group
Group type: EXPERIMENTAL
Intervention: Older cohort (IIH patients >50 years)
Number of subjects: 65
Study 32154632 — intervention group
Group type: EXPERIMENTAL
Intervention: 'disorder‐first' language
Number of subjects: 361
Study 32154632 — intervention group
Group type: EXPERIMENTAL
Intervention: 'person‐first' language
Number of subjects: 361
Study 32154632 — intervention group
Group type: EXPERIMENTAL
Intervention: 'victim' language
Number of subjects: 361
Study 32154632 — intervention group
Group type: EXPERIMENTAL
Intervention: 'recovery' language
Number of subjects: 361
Study 34839863 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative oxygen therapy
Number of subjects: 110
Study 34839863 — intervention group
Group type: COMPARATOR
Intervention: Conventional oxygen therapy
Number of subjects: 110
Study 33108123 — intervention group
Group type: EXPERIMENTAL
Intervention: Jiawei Xiaoyao (JX) pill (12 g/d, 6 g twice a day) for 4 weeks
Number of subjects: 144
Study 33108123 — intervention group
Group type: COMPARATOR
Intervention: Placebo (12 g/d, 6 g twice a day) for 4 weeks
Number of subjects: 144
Study 33108123 — intervention group
Group type: EXPERIMENTAL
Intervention: Jiawei Xiaoyao (JX) pill
Number of subjects: 144
Study 33108123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 33905053 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostering Healthy Futures (FHF) program, a 30-week mentoring and skills group preventive intervention
Number of subjects: 426
Study 33905053 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 426
Study 33905053 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostering Healthy Futures (FHF) program
Number of subjects: 426
Study 34537675 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic model including residual cancer burden index
Number of subjects: 749
Study 34537675 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk stratification model
Number of subjects: 749
Study 33084560 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency medical services (EMS) handovers
Number of subjects: 79
Study 35422171 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Frequency TENS (80-120 HZ, Intensity 15-30 amp, Pulse duration 250 Micro sec, 60 min per session)
Number of subjects: 60
Study 35422171 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Frequency TENS (1-5 HZ, Intensity 30-80 amp, Pulse duration 250 Micro sec, 60 min per session)
Number of subjects: 60
Study 35422171 — intervention group
Group type: COMPARATOR
Intervention: Routine medical care and dressing (Control)
Number of subjects: 60
Study 34868518 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine combined with dexmedetomidine group
Number of subjects: 80
Study 34868518 — intervention group
Group type: COMPARATOR
Intervention: Single lidocaine group
Number of subjects: 80
Study 34868518 — intervention group
Group type: COMPARATOR
Intervention: Single dexmedetomidine group
Number of subjects: 80
Study 34868518 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 34753557 — intervention group
Group type: EXPERIMENTAL
Intervention: RAS blockers (monotherapy or dual blockade)
Number of subjects: 70
Study 34753557 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline IL-6 levels > 4.84 pg/mL
Number of subjects: 70
Study 34753557 — intervention group
Group type: COMPARATOR
Intervention: RAS blockade (monotherapy or dual blockade)
Number of subjects: 70
Study 33600437 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraplexus injection of 25mL ropivacaine 0.5% between C5‐C6 nerve roots
Number of subjects: 208
Study 33600437 — intervention group
Group type: COMPARATOR
Intervention: Extraplexus injection of 25mL ropivacaine 0.5% anterior and posterior to the brachial plexus
Number of subjects: 208
Study 34081058 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint training (SPR) including 12 × 30‐s maximal sprints during five LIT sessions
Number of subjects: 18
Study 34081058 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON) performing distance‐matched LIT only
Number of subjects: 18
Study 34081058 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint training (SPR)
Number of subjects: 18
Study 34081058 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 18
Study 34081058 — intervention group
Group type: EXPERIMENTAL
Intervention: Neither group
Number of subjects: 18
Study 33757975 — intervention group
Group type: EXPERIMENTAL
Intervention: Information portal (intervention group)
Number of subjects: 343
Study 33757975 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 343
Study 33243209 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 1 mg/morning and 3 mg/at bedtime (Group IIIb)
Number of subjects: 152
Study 33243209 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group IIIa)
Number of subjects: 152
Study 33933267 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEK abutments (20 titanium‐supported PEEK abutments)
Number of subjects: 40
Study 33933267 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia abutments (20 zirconia abutments)
Number of subjects: 40
Study 33933267 — intervention group
Group type: COMPARATOR
Intervention: Control teeth (contralateral teeth)
Number of subjects: 40
Study 32899069 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture method of removing-stasis and resuscitating
Number of subjects: 50
Study 32899069 — intervention group
Group type: COMPARATOR
Intervention: Conventional Western medicine treatment
Number of subjects: 50
Study 34969889 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-based incentivization
Number of subjects: 30
Study 34969889 — intervention group
Group type: EXPERIMENTAL
Intervention: Streak incentivization
Number of subjects: 30
Study 34969889 — intervention group
Group type: EXPERIMENTAL
Intervention: FitBit-received flat-rate incentivization
Number of subjects: 30
Study 34969889 — intervention group
Group type: EXPERIMENTAL
Intervention: Monetary flat-rate incentivization
Number of subjects: 30
Study 34969889 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic incentivization (combined loss-based and streak)
Number of subjects: 30
Study 34969889 — intervention group
Group type: COMPARATOR
Intervention: Flat-rate incentivization (combined FitBit and monetary)
Number of subjects: 30
Study 34969889 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall symptom resolution
Number of subjects: 30
Study 33713924 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation in childhood
Number of subjects: 1268
Study 33713924 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial stimulation in childhood
Number of subjects: 1268
Study 33713924 — intervention group
Group type: COMPARATOR
Intervention: Nutritional supplementation and psychosocial stimulation interaction
Number of subjects: 1268
Study 33029267 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 ml methylene blue
Number of subjects: 15
Study 33029267 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5 ml methylene blue
Number of subjects: 15
Study 33029267 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 ml methylene blue
Number of subjects: 15
Study 33029267 — intervention group
Group type: COMPARATOR
Intervention: 3 ml methylene blue
Number of subjects: 15
Study 35568804 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy with clopidogrel plus aspirin
Number of subjects: 181
Study 35568804 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline clinical factors (carotid stenosis or occlusion, cohort type, race, baseline statin use, systolic blood pressure, serum glucose, age)
Number of subjects: 181
Study 35568804 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression model
Number of subjects: 181
Study 34248110 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-level functional capacity (HLFC)
Number of subjects: 1824
Study 34248110 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower social role in men
Number of subjects: 1824
Study 34248110 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower IADL and intellectual activity in women
Number of subjects: 1824
Study 32105092 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning algorithms with all variables
Number of subjects: 3869
Study 32105092 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple logistic regressions with all variables
Number of subjects: 3869
Study 32105092 — intervention group
Group type: EXPERIMENTAL
Intervention: Univariate logistic regressions
Number of subjects: 3869
Study 32105092 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning algorithms after removing top 5 variables
Number of subjects: 3869
Study 35580972 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung recruitment
Number of subjects: 234
Study 35580972 — intervention group
Group type: COMPARATOR
Intervention: Conventional group
Number of subjects: 234
Study 33551196 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib (150 mg orally daily for 14 days), followed by paclitaxel, carboplatin and dasatinib (daily) for six cycles (21-day cycles)
Number of subjects: 18
Study 33551196 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib
Number of subjects: 18
Study 32175587 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational materials provided at the start of aviation training (intervention group)
Number of subjects: 851
Study 32175587 — intervention group
Group type: COMPARATOR
Intervention: No educational materials provided (control group)
Number of subjects: 851
Study 32175587 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey responders in the intervention group who previously reported non-vaccine use
Number of subjects: 851
Study 36460184 — intervention group
Group type: EXPERIMENTAL
Intervention: SibChat intervention (8 sessions of 60 minutes each via video conference)
Number of subjects: 83
Study 36460184 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (WLC)
Number of subjects: 83
Study 33754705 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysophosphatidic acids (LPAs) measurement in COPD patients
Number of subjects: 200
Study 33754705 — intervention group
Group type: COMPARATOR
Intervention: Healthy donor sera
Number of subjects: 200
Study 33227131 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS over the right dorsolateral prefrontal cortex
Number of subjects: 0
Study 33227131 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulation
Number of subjects: 0
Study 33227131 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study 34210347 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined tDCS and VR-based therapy (30 minutes each)
Number of subjects: 29
Study 34210347 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy (control group)
Number of subjects: 29
Study 34210347 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined tDCS and VR-based therapy
Number of subjects: 29
Study 36190145 — intervention group
Group type: EXPERIMENTAL
Intervention: Two short implants (6 mm) with single-unit restorations (group TWO)
Number of subjects: 36
Study 36190145 — intervention group
Group type: COMPARATOR
Intervention: One single short implant (6 mm) with a cantilever restoration (group ONE-C)
Number of subjects: 36
Study 36190145 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (group ONE-C and group TWO)
Number of subjects: 36
Study 36190145 — intervention group
Group type: EXPERIMENTAL
Intervention: Group ONE-C
Number of subjects: 36
Study 36190145 — intervention group
Group type: COMPARATOR
Intervention: Group TWO
Number of subjects: 36
Study 36190145 — intervention group
Group type: EXPERIMENTAL
Intervention: Implants that survived
Number of subjects: 36
Study 34077539 — intervention group
Group type: EXPERIMENTAL
Intervention: FDA-required nicotine warning
Number of subjects: 1152
Study 34077539 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 cigarettes warning
Number of subjects: 1152
Study 32653248 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-based injury prevention program (IPP) for 8 weeks
Number of subjects: 8
Study 32653248 — intervention group
Group type: COMPARATOR
Intervention: Normal cricket activity (Control)
Number of subjects: 8
Study 36034130 — intervention group
Group type: EXPERIMENTAL
Intervention: Yijinjing Qigong Exercise (YJJQE)
Number of subjects: 60
Study 36034130 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine segmental rehabilitation training)
Number of subjects: 60
Study 32112126 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve block, continuous sciatic nerve block and single‐shot obturator nerve block (group R)
Number of subjects: 140
Study 32112126 — intervention group
Group type: COMPARATOR
Intervention: Local infiltration analgesia and a continuous intraarticular catheter with ropivacaine (group L)
Number of subjects: 140
Study 35756982 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraneural facilitation
Number of subjects: 10
Study 35756982 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 10
Study 35237863 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric citrate
Number of subjects: 0
Study 35237863 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34119909 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS treatment
Number of subjects: 157
Study 34119909 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS treatment
Number of subjects: 157